Rhabdomyolysis in the Setting of Concomitant Use of Tafamidis, Atorvastatin, and Amiodarone.

ALT, alanine aminotransferase AST, aspartate aminotransferase ATTR, transthyretin amyloidosis BCRP, breast cancer receptor protein CK, creatinine kinase CYP3A4, cytochrome P-450 3A4 pathway LFT, liver function test atherosclerosis cardiomyopathy restrictive

Journal

JACC. Case reports
ISSN: 2666-0849
Titre abrégé: JACC Case Rep
Pays: Netherlands
ID NLM: 101757292

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 19 06 2020
revised: 25 08 2020
accepted: 22 09 2020
entrez: 28 7 2021
pubmed: 29 7 2021
medline: 29 7 2021
Statut: epublish

Résumé

An 85-year-old women with transthyretin cardiac amyloidosis presented with generalized weakness, elevated liver function test levels, and creatinine kinase consistent with rhabdomyolysis 1 week after starting tafamidis. She was already taking atorvastatin and amiodarone, raising the possibility of a drug-drug interaction inhibiting the breakdown and excretion of atorvastatin, causing drug-induced rhabdomyolysis. (

Identifiants

pubmed: 34317174
doi: 10.1016/j.jaccas.2020.09.037
pii: S2666-0849(20)31189-X
pmc: PMC8304530
doi:

Types de publication

Case Reports

Langues

eng

Pagination

2372-2375

Informations de copyright

© 2020 The Authors.

Déclaration de conflit d'intérêts

The Brigham and Women's/Dana Faber Amyloidosis Program is supported by Leslie and Howard Appleby and the Harold Grinspoon Charitable Foundation. Dr. Falk has received consulting fees from Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and Caelum Biosciences; and research funding from GlaxoSmithKline, Akcea, and Pfizer. Dr. Cuddy has received an investigator-initiated research grant from Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Références

Bone Marrow Transplant. 2005 Oct;36(8):739-40
pubmed: 16086041
J Am Coll Cardiol. 2006 Apr 18;47(8):1724-5
pubmed: 16631014
J Am Coll Cardiol. 2020 Mar 24;75(11):1341-1350
pubmed: 32192661
J Pharmacol Exp Ther. 2010 Jun;333(3):788-96
pubmed: 20304939
Lancet. 2016 Jun 25;387(10038):2641-2654
pubmed: 26719234
Genet Med. 2017 Jul;19(7):733-742
pubmed: 28102864
Clin Pharmacol Ther. 2009 Aug;86(2):197-203
pubmed: 19474787
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929

Auteurs

Jessica Laird (J)

Harvard Medical School, Boston, Massachusetts, USA.

Rodney H Falk (RH)

Harvard Medical School, Boston, Massachusetts, USA.
Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Melissa Coyle (M)

Partners HealthCare Specialty Pharmacy, Burlington, Massachusetts, USA.

Sarah A M Cuddy (SAM)

Harvard Medical School, Boston, Massachusetts, USA.
Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
CV Imaging Program, Cardiovascular Division, Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Classifications MeSH